Safety and Immunogenicity of the Protein-Based PHH-1V Compared to BNT162b2 As a Heterologous SARS-CoV-2 Booster Vaccine in Adults Vaccinated Against COVID-19: a Multicentre, Randomised, Double-Blind, Non-Inferiority Phase IIb Trial Julia Corominas , Carme Garriga , Antoni Prenafeta , Alexandra Moros , Manuel Canete , Antonio Barreiro , Luis Gonzalez-Gonzalez , Laia Madrenas , Irina Guell , Bonaventura Clotet , Nuria Izquierdo-Useros , Dalia Raich-Regue , Marcal Gallemi , Julia Blanco , Edwards Pradenas , Benjamin Trinite , Julia G. Prado , Oscar Blanch-Lombarte , Raul Perez-Caballero , Montserrat Plana , Ignasi Esteban , Carmen Pastor-Quinones , Xavier Nunez-Costa , Rachel Abu Taleb , Paula McSkimming , Alex Soriano , Jocelyn Nava , Jesse Omar Anagua , Rafel Ramos , Ruth Marti Lluch , Aida Corpes Comes , Susana Otero Romero , Xavier Martinez Gomez , Carla Sans-Pola , Jose Molto , Susana Benet , Lucia Bailon , Jose R. Arribas , Alberto M. Borobia , Javier Queiruga Parada , Jorge Navarro-Perez , Maria Jose Forner Giner , Rafael Orti Lucas , Maria del Mar Vazquez Jimenez , Salvador Ona Compan , Melchor Alvarez-Mon , Daniel Troncoso , Eunate Arana-Arri , Susana Meijide , Natale Imaz-Ayo , Patricia Munoz Garcia , Sofia de la Villa Martinez , Sara Rodriguez Fernandez , Teresa Prat , Elia Torroella , Laura Ferrer The Lancet Regional Health - Europe（2023）
Key words
SARS-CoV-2, Protein-based vaccine, Heterologous boost, SARS-CoV-2 variants, Neutralizing antibodies
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
